Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02097173 · ClinicalTrials.gov registry record · Phase 1

Bioavailability in Patient With Psoriasis: Metoject Prefilled Pen

A Phase 1 study, sponsored by medac.

Completed
Registry status
Phase 1
Development phase
35
Enrollment target

NCT02097173 is a Phase 1 study that has completed, run by medac. The registered enrollment target is 35 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02097173, a Phase 1 study, has completed, sponsored by medac.

COMPLETED
Registry status
Phase 1
Development phase
35 participants
Enrollment target

Study Summary

This study is conducted to assess the relative bioavailability of MTX administered subcutaneously via a prefilled pen (50mg/mL) compared with MTX administered via IM injection (25mg/mL).

Interventions

  • DRUG Methotrexate

Trial Details

FieldValue
Enrollment Target 35 participants
Start Date 2013-05
Phase Phase 1

Sponsor

medac

4 total trials

What the Registry Record Tells You About NCT02097173

The ClinicalTrials.gov registry entry for NCT02097173 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is medac, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Methotrexate is the first listed.

NCT02097173 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02097173 about?

NCT02097173 is a clinical study titled "Bioavailability in Patient With Psoriasis: Metoject Prefilled Pen". This study is conducted to assess the relative bioavailability of MTX administered subcutaneously via a prefilled pen (50mg/mL) compared with MTX administered via IM injection (25mg/mL).

What is the current status of trial NCT02097173?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2013-05.

What interventions are being tested in trial NCT02097173?

The interventions under investigation include: Methotrexate (DRUG).

Who is sponsoring clinical trial NCT02097173?

This trial is sponsored by medac, which has 4 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.